JP2016528247A5 - - Google Patents

Info

Publication number

JP2016528247A5

JP2016528247A5 JP2016533986A JP2016533986A JP2016528247A5 JP 2016528247 A5 JP2016528247 A5 JP 2016528247A5 JP 2016533986 A JP2016533986 A JP 2016533986A JP 2016533986 A JP2016533986 A JP 2016533986A JP 2016528247 A5 JP2016528247 A5 JP 2016528247A5

Authority

JP

Japan

Prior art keywords

seq

chain variable

variable region

heavy chain

light chain

Prior art date

2014-08-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001413 amino acids Chemical class 0.000 claims description 84
• 201000008319 inclusion body myositis Diseases 0.000 claims description 57
• 239000005557 antagonist Substances 0.000 claims description 48
• 102000004472 Myostatin Human genes 0.000 claims description 47
• 108010056852 Myostatin Proteins 0.000 claims description 47
• 239000000203 mixture Substances 0.000 claims description 42
• 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 24
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
• 230000037396 body weight Effects 0.000 claims description 16
• 102000005962 receptors Human genes 0.000 claims description 8
• 108020003175 receptors Proteins 0.000 claims description 8
• 208000019505 Deglutition disease Diseases 0.000 claims description 4
• 239000002464 receptor antagonist Substances 0.000 claims description 4
• 229940044551 receptor antagonist Drugs 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
• 206010061818 Disease progression Diseases 0.000 claims description 3
• 230000005750 disease progression Effects 0.000 claims description 3
• 239000012636 effector Substances 0.000 claims description 3
• 238000001802 infusion Methods 0.000 claims description 3
• 210000003205 muscle Anatomy 0.000 claims description 3
• 230000035772 mutation Effects 0.000 claims description 3
• 210000001364 upper extremity Anatomy 0.000 claims description 3
• 230000000903 blocking effect Effects 0.000 claims description 2
• 239000002552 dosage form Substances 0.000 claims description 2
• 230000009747 swallowing Effects 0.000 claims description 2
• 230000001225 therapeutic effect Effects 0.000 claims 2
• 230000004899 motility Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 34
• 239000003814 drug Substances 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 210000003000 inclusion body Anatomy 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1